ARTICLE | Top Story
CVTX down on CARISA update
January 5, 2001 8:00 AM UTC
CV Therapeutics was off $21.25 (35 percent) to $39.625 on Friday after announcing it will enroll an additional 186 patients in its Phase III Combination Assessment of Ranolazine in Stable Angina (CARI...